An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrials